Abstract: Provided herein are compositions, systems, and methods for prediction of a chemosensitivity to cisplatin or other platinum based drugs for cancer. In certain embodiments, the methods comprise receiving results of, or conducting, an mRNA and/or protein expression level analysis of at least one gene (e.g., 1-13 or 1-19 genes) in a tumor sample from a subject, wherein the gene is expressed at higher levels than a control and is selected from: ADA, NPM3, CSTA, KRT5, KRT14, ATP1B3, USP31, MAP7D3, LRRC8C, C15orf41, LY6K, BNC1, SLFN11, ADAT2, CDIN1, C1QBP, CDC7, CDCA7, FKBP14, MMP10, PSAT1, RIOK1, STOML2, WDR3, and ZNF750; and treating said subject with Cisplatin or other platinum based cancer drug.